Vera Therapeutics, Inc.

NASDAQ•VERA

CEO: Dr. Marshall W. Fordyce M.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-05-14

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Contact Information

8000 Marina Boulevard, Suite 120, Brisbane, CA, 94005, United States

650-770-0077

veratx.com

Market Cap

$3.02B

P/E (TTM)

-9.1

18.2

Dividend Yield

52W High

$56.05

52W Low

$18.76

52W Range

63%

Rank69Top 98.7%

1.2

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 1.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$1.39+0.00%

4-Quarter Trend

FCF

-$70.10M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Atacicept Pivotal Trial Success ORIGIN 3 Phase 3 trial met primary endpoint in June 2025; BLA submitted November 2025 with July 7, 2026 PDUFA date.

Significant Cash Position Growth Cash and marketable securities reached $354.7M by December 31, 2025, up from $92.6M in 2024, funded by offerings.

Pipeline Expansion Secured Acquired worldwide rights to VT-109, a novel BAFF/APRIL inhibitor, in January 2025 via Stanford license agreement.

Operating Losses Widened Net loss increased 97% to $(299.6M) in 2025, driven by R&D expenses rising 71% to $215.3M USD.

Risk Factors

Substantial Capital Required Requires substantial additional capital to finance operations; inability to raise funds forces program delays or elimination.

No Revenue Generated Yet Incurred net losses since inception; never generated revenue from product sales; expects continued losses for several years.

Loan Agreement Restrictions 2025 Loan Agreement imposes covenants limiting financial flexibility; default could accelerate repayment obligations immediately.

Dependence on Product Success Business heavily dependent on timely development, regulatory approval, and commercialization of product candidates like atacicept.

Outlook

Atacicept Launch Readiness Building specialized commercial organization to support potential U.S. launch of atacicept in key markets, if regulatory approval is granted.

Pipeline Data Expected 2026 Anticipate clinical results from ORIGIN EXTEND and PIONEER phase 2 trials during the 2026 calendar year for pipeline assets.

Advance VT-109 Development Plan to advance VT-109 development and explore its potential across multiple B-cell mediated disease indications in preclinical stage.

Peer Comparison

Revenue (TTM)

HRMY

$868.45M

+21.5%

STOK

$184.42M

+404.5%

LQDA

$158.32M

+1031.2%

Gross Margin (Latest Quarter)

LQDA

101.7%

+29.3pp

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
COGT	$6.05B	-7.7	-100.2%	27.0%
CELC	$5.92B	-36.3	-203.2%	41.9%
LQDA	$3.48B	-49.9	-209.3%	60.4%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 4, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data